结核病领域研究进展(2020年度)

结核病是严重危害人类健康的传染性疾病之一,是全球单一传染病致死的十大死亡原因之一。2020年全球结核病研究领域学者做出了诸多努力,在结核病基础、诊断、治疗和预防等方面研究均有很多突破。这些突破给结核病防治科技工作者带来了很多的启发和思路,也为临床治疗带来了更多的希望,例如:结核分枝杆菌Sulfolipid-1的致咳机制研究带来了控制结核分枝杆菌传染的新思路;M72/AS01_E疫苗的良好保护效果让我们看到继卡介苗之后的新希望;Nix-TB的研究结果为复治或难治耐多药/广泛耐药结核病(MDR/XDR-TB)患者带来了新的曙光;mRNA标记物等新型诊断方法研究也在不断取得进步。为了提高全国结核病防治人员的诊疗能力,及时了解全球结核病研究在新技术、新方法、新理念和新药物研发上的突破,中国防痨协会组织专家对2019年10月至2020年10月于国际上发表的重要文献进行解读,以期为推动我国结核病领域研究工作做出贡献。

Tuberculosis research progress in 2020

Tuberculosis (TB) is one of the most serious infectious diseases, and one of the top ten death causes of single infectious disease globally. In 2020, researchers have made many efforts, and many breakthroughs have been made in basic research, diagnosis, treatment and prevention on TB. These breakthroughs have brought a lot of inspiration and ideas to TB research, and also brought more hope for clinical work. For example, the research on the cough mechanism of MTB sulfolipid-1 has brought new ideas to control the infection of MTB. The good protective effect of M72/AS01_E vaccine gave us hope for TB prevention after BCG. The results of the Nix-TB study bring new light to the retreated or refractory MDR/XDR-TB patients. New diagnostic methods such as mRNA markers are also making progress. In order to improve the diagnosis and treatment ability of national TB prevention and control personnel, and timely understand the breakthrough of global TB research in new technologies, new methods, new concepts and new drug research, Chinese Antituberculosis Association organized experts to interpret the important literatures published internationally from October 2019 to October 2020, so as to contribute to promoting the research work in the field of TB in China.